eltrombopag ITP
Selected indexed studies
- Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. (Blood, 2017) [PMID:29042367]
- A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP. (Br J Haematol, 2023) [PMID:37339869]
- Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial. (Blood, 2024) [PMID:38958479]
_Worker-drafted node — pending editorial review._
Connections
eltrombopag ITP is a side effect of
Sources
- Eltrombopag. (2011) pubmed
- Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. (2017) pubmed
- Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. (2024) pubmed
- A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP. (2023) pubmed
- Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial. (2024) pubmed
- Ianalumab plus Eltrombopag in Immune Thrombocytopenia. (2026) pubmed
- Thrombopoietin receptor agonists: ten years later. (2019) pubmed
- Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). (2011) pubmed
- Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients. (2021) pubmed
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial. (2025) pubmed